DNA strand and X chromosome
Credit: SpiffyJ / Getty Images / E+

A groundbreaking study has used cutting-edge epigenome editing technologies to advance understanding and potential treatments for Prader-Willi syndrome (PWS), a complex neuroendocrine and neurobehavioral disorder caused by DNA imprinting. The study, published in Cell Genomics, highlights the transformative potential of precision epigenome editing in therapeutic development.

Unlocking epigenetic mysteries

Although extensive research has been conducted on the identity and dynamics of epigenetic marks, the mechanisms driving heritable and allele-specific gene expression changes remain unclear. Scientists have turned to advanced tools, such as CRISPR-Cas9, to manipulate gene expression and epigenetic states in living cells with unprecedented precision.

Using nuclease-deactivated Cas9 (dCas9) fused with transcriptional regulators or epigenome modifiers, researchers can target specific DNA regions to alter chromatin marks, modify DNA methylation, or influence transcriptional activity. These techniques provide insights into gene regulation and identify critical regulatory elements in the genome, which could serve as potential drug targets for next-generation therapies.

Focus on Prader-Willi syndrome

PWS is caused by the absence of expression of paternal imprinted genes within the 15q11–13 chromosomal region. Patients exhibit symptoms such as hyperphagia, early-onset obesity, and intellectual disability. In approximately 70% of cases, PWS is linked to deletions of the paternal allele, with two main subtypes—Type I and Type II—defined by the size and location of the deleted region.

The small nucleolar RNA (snoRNA) gene cluster, SNORD116, located downstream of the SNURF-SNRPN open reading frame within 15q11–13 as a likely primary contributor to the disease etiology, has been identified as a primary contributor to the disease. However, loss of SNORD116 expression may not be required to elicit classic PWS symptoms, as there is another report of an unusual 78-kb microdeletion that spans only SNRPN exons 2 and 3 and maintains SNORD116 expression in a patient with a typical PWS phenotype.

Since the maternal copy of the 15q11–13 region remains intact but epigenetically silenced, researchers have explored activating the maternal allele as a therapeutic strategy. While small-molecule inhibitors targeting epigenetic modifiers have shown some promise, concerns about off-target effects have spurred interest in more precise approaches.

A precision epigenome editing approach

In the latest study, researchers applied CRISPR-dCas9-based tools to map and manipulate regulatory elements within the 15q11–13 locus. They identified key elements controlling gene expression by conducting separate screens on the paternal and maternal alleles in human induced pluripotent stem cells (iPSCs) of PWS patients.

The study demonstrated that silenced maternal SNRPN and downstream PWS-associated transcripts can be reactivated through two distinct strategies: targeted transcriptional activation or DNA demethylation. Interestingly, these approaches operate via unique mechanisms, preferentially activating different transcript variants and triggering distinct epigenetic reprogramming processes.

Implications for targeted therapy

This research complements earlier efforts using small-molecule inhibitors to reactivate imprinted genes and highlights the potential of CRISPR-based technologies for targeted epigenetic therapy. By focusing on specific loci with minimal off-target effects, these tools offer a promising avenue for addressing the root causes of PWS and similar disorders.

However, this study does not determine the physiological significance of activating SNRPN or SNORD116 or clarify the relevance of expressing specific SNRPN/SNHG14 transcripts. As a result, the therapeutic potential of partially activating PWS-associated transcripts remains uncertain. To build on what was found in iPSCs, more research is needed to determine what stops scientists from directly activating the PWS locus in neurons or other post-mitotic cells.

Also of Interest